Associated Papers
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD).
Pinto E Vairo F et al.
Journal of Translational Medicine, 2023
37353797 (PubMed )
Supplement: 12967_2023_4183_MOESM3_ESM.xlsx › Table_S3
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing.
Kleftogiannis D et al.
Scientific Reports, 2020
Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J et al.
Breast Cancer Research : Bcr, 2018
Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.
Sanders H et al.
Molecular Diagnosis & Therapy, 2016
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
Lupini L et al.
Bmc Cancer, 2015
26508446 (PubMed )
Supplement: 12885_2015_1752_MOESM3_ESM.xlsx › Foglio1
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
Select a paper to view details